



Aviragen Therapeutics, Inc.  
Investor Relations Department  
2500 Northwinds Parkway  
Suite 100  
Alpharetta, GA 30009  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

**NASDAQ: AVIR**

Last Trade:	0.56
Trade Time:	3:56 PM ET Nov 17, 2017
Change:	-0.01 <span style="color: red;">↓</span> (-1.651%)
Day Range	0.55 - 0.58
52-Week Range	0.43 - 1.60
Volume	165,239

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Aviragen Therapeutics is focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three Phase 2 clinical stage compounds: varendavir, a capsid inhibitor for the prevention or treatment of rhinovirus (RV) upper respiratory infections; enzaplavovir (BTA585), a fusion protein inhibitor in development for the treatment of respiratory syncytial virus infections; and BTA074, an antiviral treatment for condyloma caused by human papill... [\(more\)](#)

## Stock Information



## Press Releases [\[ View all \]](#)

- Nov 2, 2017 [Aviragen Therapeutics Reports First Quarter of Fiscal Year 2018 Financial Results](#)
- Oct 30, 2017 [Aviragen Therapeutics and Vaxart Enter into Merger Agreement](#)
- Aug 31, 2017 [Aviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results](#)
- May 4, 2017 [Aviragen Therapeutics Reports Third Quarter Fiscal Year 2017 Financial Results](#)
- Apr 4, 2017 [Aviragen Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update](#)

## Financials [\[ View all \]](#)

- [First Quarter Financial Results](#)
- Sep 1, 2017 [Annual Report \(10-K\)](#)
- Sep 27, 2016 [Proxy Statement \(DEF 14A\)](#)
- Nov 7, 2017 [Quarterly Report \(10-Q\)](#)
- May 8, 2017 [Quarterly Report \(10-Q\)](#)
- Feb 6, 2017 [Quarterly Report \(10-Q\)](#)